Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009421 | 0.90 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRPOLBENPP2 | |
| SCHEMBL1009275 | 0.82 | PTGDR2 (0.57) | PTGDR2TBXA2RPTGDRPOLBENPP2 | |
| SCHEMBL1010718 | 0.81 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRKDM1AMAOA | |
| SCHEMBL8739208 | 0.78 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRKDM1AMAOA | |
| SCHEMBL1010070 | 0.77 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRPOLBENPP2 | |
| SCHEMBL8738296 | 0.76 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRKDM1AMAOA | |
| SCHEMBL10206853 | 0.76 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRPOLBENPP2 | |
| SCHEMBL10206856 | 0.74 | PTGDR2 (0.55) | PTGDR2KDM1AMAOAMAOBPOLB | |
| SCHEMBL1010670 | 0.73 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL1008677 | 0.73 | PTGDR2 (0.47) | PTGDR2TBXA2RPTGDRPOLBENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | PTGDR2 11/4885TBXA2R 20/4885PTGDR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.